Endolytix
Beverly
About Endolytix
Endolytix is a biotech company that develops therapeutic approaches that address intrinsic antibiotic resistance in NTM infections. Its therapeutics kill pathogenic bacteria, including multidrug-resistant bacteria, and help the healthcare industry address the most resistant antibiotic infections that are difficult to access and treat.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.3M
- Last round: Debt Financing (Aug 2024)
- Website: endolytx.bio
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/endolytix-9757 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.